RE:Early Adopter Stage with KNRWe all overestimated how sizeable the early adoption will be but in retrospect we should have intuitively know for the price of BioCloud there will be trials and sales would come quicker once they can point to new clients the relatively extensive client base that had tested and purchased the product. The quick easy buck was not there, so now it is decision time: stick it out, or come back later when sales can be projected. But at that time you could be buying in af higher levels since seeing good sales will move the price up. I am sticking it out due to the market cap that is not astronomical with the core business and even 100 BioClouds per month when we get going on average. This is all pending company information which could change things in a jiffy.